Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study

Abstract Background Despite the availability of new direct-acting antiviral (DAA) regimens, changes in DAA reimbursement criteria, and a public health focus on hepatitis C virus (HCV) elimination, it remains unclear if public and private insurers have increased access to these therapies over time. W...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Open forum infectious diseases 2018-06, Vol.5 (6), p.ofy076
Hauptverfasser:	Gowda, Charitha, Lott, Stephen, Grigorian, Matthew, Carbonari, Dena M, Saine, M Elle, Trooskin, Stacey, Roy, Jason A, Kostman, Jay R, Urick, Paul, Lo Re, Vincent
Format:	Artikel
Sprache:	eng
Schlagworte:	Editor's Choice Major
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!